Skip to content
New: 100+ more US companies, including the big banks, plus insider trades from SEC filings

Health Care · NYSE: RDY

Dr. Reddy's: how the business works

Dr. Reddy's, a drug maker based in Hyderabad, India, sells generic medicines, mostly in North America, and branded medicines in India and emerging markets, with revenue of INR 335,933 million in FY2026 (year ended Mar 31, 2026).

By · Checked against filings: . Editorial policy. Corrections

Follow Dr. Reddy's

Email me when Dr. Reddy's's page is updated after earnings.

We'll send a confirmation email first. See our privacy policy.

Dr. Reddy's Laboratories Limited · Hyderabad, India · Founded 1984

Updated for Q2 FY2027 · checked

Revenue, FY2026
INR 335,933 million
Profit for equity holders, FY2026
INR 42,850 million
Revenue, Q2 FY2027 (INR 88,051 million a year earlier)
INR 86,708 million
Employees, Mar 31, 2026
27,527
Held by the two founding families and their trusts, Mar 31, 2026
26.63%

For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

The short version

Dr. Reddy's in 5 points

  1. 1 · What it sells

    Dr. Reddy's sells generic and branded medicines and drug ingredients; its Global Generics segment brought in INR 299,033 million of FY2026 revenue of INR 335,933 million.

    More: what it sells

  2. 2 · Who pays it

    North America paid 33.9% of FY2026 revenue, India 18.5%, Europe 16.5%, Russia 10.4%, other CIS countries and Romania 2.7%, the rest of the world 7.1%, ingredient and service buyers 10.4% and others 0.6%.

    More: who pays it

  3. 3 · What it keeps from INR 100

    Of every INR 100 that came in during FY2026, including INR 12,277 million of other income, net finance income, its share of associates' profit and the minority partner's losses, Dr. Reddy's kept INR 12.3 as profit; operating profit, which included one-off trademark and settlement gains, was INR 15.0 per INR 100 of revenue.

    More: what it keeps from inr 100

  4. 4 · Where the operating profit comes from

    Dr. Reddy's reports segment profit only down to gross profit: Global Generics earned INR 169,698 million of FY2026's INR 177,264 million, PSAI INR 5,984 million and Others INR 1,582 million.

    More: where the operating profit comes from

  5. 5 · The one thing to watch

    North America revenue was INR 24,890 million in Q2 FY2027, against INR 32,408 million a year earlier, while emerging markets revenue rose to INR 20,595 million from INR 16,548 million.

    More: the one thing to watch

Sources: From Dr. Reddy's Form 20-Fs for FY2022 to FY2026 and its Form 6-K results · checked

01Where the money goes · FY2026

Where does INR 100 of Dr. Reddy's' money go?

Of every INR 100 that came in (revenue plus other income), this is where it went.

Dr. Reddy's · FY2026

Receipt for every INR 100

Where INR 100 of Dr. Reddy's' money went in FY2026
Cost of revenues (making the products)INR 45.6
Selling, general and administrativeINR 30.7
Research and developmentINR 6.9
Impairment (write-downs of assets)INR 1.0
Income taxINR 3.5
Kept as profit for equity holdersINR 12.3
TotalINR 100

Each line = amount ÷ total money in × 100. Lines may not add to exactly INR 100 because of rounding.

How this is worked out

Cityfort calculation from the FY2026 20-F. Of every INR 100 that came in during FY2026 (revenue of INR 335,933 million plus INR 12,277 million of other income, finance income, share of associates' profit and the minority partner's INR 384 million share of losses): each line = line ÷ INR 348,210 million × 100.

Save this receipt as an image

Embed this receipt or the key numbers

Paste this code into a blog or website to show the card you choose, with a link back to this page.

Each week: the next company due to report earnings, explained in 5 points.

No tips. Unsubscribe anytime.

We'll send a confirmation email. See our privacy policy.

02The business in one line

What does Dr. Reddy's do?

Wholesalers, pharmacy chains and hospitals pay Dr. Reddy's for medicines; after costs and tax, it kept INR 12.3 of every INR 100 that came in during FY2026 as profit.

  • North America brought in 33.9% of FY2026 revenue, down from 44.6% in FY2025, after sales there fell 22% (Cityfort calculation from the FY2026 20-F).
  • Revenue rose 3% to INR 335,933 million in FY2026, while profit for equity holders fell from INR 56,544 million to INR 42,850 million.

03Who pays it

Who pays Dr. Reddy's?

  • North America

    33.9%

    of revenue

    Mostly retail chains, wholesalers and private-label customers. Revenue was INR 113,737 million in FY2026, down 22% from FY2025.

  • India

    18.5%

    of revenue

    Sold through agents to about 6,500 wholesalers, who sell on to retailers. Revenue was INR 62,186 million, up 16%.

  • Europe

    16.5%

    of revenue

    Revenue was INR 55,501 million, up 55%, including INR 28,189 million from the nicotine replacement brands bought from Haleon.

  • Russia

    10.4%

    of revenue

    Revenue was INR 34,786 million in FY2026.

  • Other CIS countries and Romania

    2.7%

    of revenue

    Revenue was INR 9,074 million in FY2026.

  • Rest of the world

    7.1%

    of revenue

    Revenue was INR 23,749 million in FY2026.

  • Drug makers buying ingredients and services (PSAI)

    10.4%

    of revenue

    External revenue was INR 34,773 million, not counting INR 7,270 million sold to Dr. Reddy's own Global Generics unit.

  • Others

    0.6%

    of revenue

    INR 2,127 million, mainly from Aurigene Oncology, a drug-discovery subsidiary, and proprietary products.

  • North America33.9%
  • India18.5%
  • Europe16.5%
  • Russia10.4%
  • Other CIS countries and Romania2.7%
  • Rest of the world7.1%
  • Drug makers buying ingredients and services (PSAI)10.4%
  • Others0.6%

How spread out the customers are

Shares are of FY2026 revenue by market (Cityfort calculation from the FY2026 20-FThe annual report a foreign company listed in the US files with the SEC, in place of a 10-K. Learn more). In North America, most revenue comes from retail chains, wholesalers and private-label customers; in India, Dr. Reddy's sells to about 6,500 wholesalers.

04How it makes money

How does Dr. Reddy's make money?

Dr. Reddy's earns almost all of its gross profit from finished medicines, and its operating profit per INR 100 of revenue fell from INR 22.1 in FY2025 to INR 15.0 in FY2026.

Global Generics earned INR 169,698 million of FY2026's INR 177,264 million of gross profit, and PSAI INR 5,984 million. Operating profit per INR 100 of revenue ranged from INR 13.7 to INR 24.3 between FY2022 and FY2026.

Operating profit per INR 100 of revenue

INR 22.1INR 15.0

FY2025 to FY2026

  1. It applies to sell copies of medicines as patents expire: 80 US applications were pending at Sep 30, 2026
  2. The first approved copy usually wins a large share; as rivals arrive, sales and gross profit typically decline, the 20-F says
  3. Branded businesses in India, emerging markets and the nicotine brands made 53% of Q2 FY2027 revenue, by the company's count
  4. Operating profit was INR 15.0 per INR 100 of revenue in FY2026
  5. Cash from operations, INR 56,755 million in FY2026, pays for factories, product rights, dividends and acquisitions

↺ Step 5 feeds back into step 1.

05Business segments · FY2026

Which businesses make up Dr. Reddy's?

  • Global Generics

    89%

    Finished medicines in all markets, including biosimilars and the nicotine brands. Segment gross profit was INR 169,698 million, 56.7% of its revenue.

    Revenue INR 299,033M

  • PSAI (drug ingredients and services)

    10.4%

    Active ingredients and contract research and manufacturing. Segment gross profit was INR 5,984 million, 17.2% of its revenue, against 27.1% in FY2025.

    Revenue INR 34,773M

  • Others

    0.6%

    Aurigene Oncology, a drug-discovery subsidiary, and proprietary products. Segment gross profit was INR 1,582 million.

    Revenue INR 2,127M

How the mix changed

  • Global Generics
  • PSAI (drug ingredients and services)
  • Others

Revenue by segment, FY2024 to FY2026.

INR million

See the numbers
How the mix changed (INR million)
YearGlobal GenericsPSAI (drug ingredients and services)Others
FY2024INR 245,453MINR 29,801MINR 3,910M
FY2025INR 289,552MINR 33,846MINR 2,137M
FY2026INR 299,033MINR 34,773MINR 2,127M

06The numbers · Consolidated · INR million

How has Dr. Reddy's done?

Dr. Reddy's files a Form 20-F each year and furnishes quarterly results on Form 6-KHow a foreign company listed in the US furnishes the SEC with reports it publishes at home, such as quarterly results. It is not a 10-Q. Learn more, as a foreign private issuerA non-US company that the SEC lets file a 20-F instead of a 10-K. It files no US proxy statement. Learn more. Its financial statements follow IFRSInternational Financial Reporting Standards: accounting rules set by the International Accounting Standards Board. The SEC accepts them from foreign companies in place of US GAAP. (International Financial Reporting Standards, as issued by the IASB) and are reported in Indian rupees, shown here as filed in INR million (not converted to dollars). Quarterly figures: IFRS as issued by the IASB, in INR, from the quarterly results furnished on Form 6-K; unaudited, with a limited review by the auditors.

Dr. Reddy's 20-F uses IFRS as issued by the IASB, in Indian rupees, so amounts show in INR million as filed, never converted. EPS reflects the five-for-one split of October 2024; no comparable FY2022 EPS is filed, so that year is blank.

Revenue

INR 335,933MFY2026

Revenue rose every year from INR 214,391 million in FY2022 to INR 335,933 million in FY2026; Q2 FY2027 revenue was 1.5% below a year earlier.

INR million

See the numbers
Revenue (INR million)
PeriodRevenue (INR million)
FY2022INR 214,391M
FY2023INR 245,879M
FY2024INR 279,164M
FY2025INR 325,535M
FY2026INR 335,933M
Q3 FY2025INR 83,586M
Q4 FY2025INR 85,060M
Q1 FY2026INR 85,452M
Q2 FY2026INR 88,051M
Q3 FY2026INR 87,268M
Q4 FY2026INR 75,162M
Q1 FY2027INR 80,705M
Q2 FY2027INR 86,708M

Net income

INR 42,850MFY2026

Profit for equity holders was INR 42,850 million in FY2026, down from INR 56,544 million; Q4 FY2026, at INR 2,201 million, was the lowest of the eight quarters shown and included a lenalidomide claim of INR 4,530 million against revenue.

INR million

See the numbers
Net income (INR million)
PeriodNet income (INR million)EPS (INR)
FY2022INR 23,568M–
FY2023INR 45,067MINR 54.17
FY2024INR 55,684MINR 66.80
FY2025INR 56,544MINR 67.78
FY2026INR 42,850MINR 51.42
Q3 FY2025INR 14,133MINR 16.94
Q4 FY2025INR 15,939MINR 19.11
Q1 FY2026INR 14,178MINR 17.02
Q2 FY2026INR 14,372MINR 17.25
Q3 FY2026INR 12,098MINR 14.52
Q4 FY2026INR 2,201MINR 2.64
Q1 FY2027INR 4,435MINR 5.32
Q2 FY2027INR 9,250MINR 11.10

Net income for every INR 100 of revenue

INR 12.8FY2026

EBITDA per INR 100 of revenue ranged from INR 19.3 to INR 29.6 between FY2022 and FY2026; EBITDA here is a Cityfort calculation from the Form 20-Fs (operating profit plus depreciation and amortization) and differs from the company's own EBITDA (FY2026: INR 76,595 million).

Net margin: INR of net income per INR 100 of revenue

See the numbers
Net income for every INR 100 of revenue (Net margin: INR of net income per INR 100 of revenue)
YearNet marginEBITDA margin
FY202211.0%19.3%
FY202318.3%28.4%
FY202419.9%29.6%
FY202517.4%27.3%
FY202612.8%21.2%

Free cash flow

INR 33,429MFY2026

Free cash flow (cash from operations minus spending on property, plant and equipment) was INR 33,429 million in FY2026; it leaves out the INR 15,099 million spent on product rights and other intangible assets.

INR million · cash from operations minus spending on plants and equipment

See the numbers
Free cash flow (INR million · cash from operations minus spending on plants and equipment)
YearCash from operationsCapital spendingFree cash flow
FY2022INR 28,108MINR 14,660MINR 13,448M
FY2023INR 58,875MINR 11,323MINR 47,552M
FY2024INR 45,433MINR 16,403MINR 29,030M
FY2025INR 46,428MINR 27,504MINR 18,924M
FY2026INR 56,755MINR 23,326MINR 33,429M
See all yearly numbers
Dr. Reddy's annual financials, FY2022–FY2026, INR million
YearRevenueEBITDANet incomeEPS (INR)Operating cashCapexFree cash
FY2022INR 214,391MINR 41,300MINR 23,568M–INR 28,108MINR 14,660MINR 13,448M
FY2023 (restated)INR 245,879MINR 69,780MINR 45,067MINR 54.17INR 58,875MINR 11,323MINR 47,552M
FY2024 (restated)INR 279,164MINR 82,570MINR 55,684MINR 66.80INR 45,433MINR 16,403MINR 29,030M
FY2025INR 325,535MINR 88,901MINR 56,544MINR 67.78INR 46,428MINR 27,504MINR 18,924M
FY2026INR 335,933MINR 71,156MINR 42,850MINR 51.42INR 56,755MINR 23,326MINR 33,429M

EBITDA here = operating income plus depreciation and amortization (from the cash flow statement). Fiscal years are the company's own: Mar 31 (fiscal 2026 = Apr 1, 2025 to Mar 31, 2026). EPS is per equity share, as filed. One American depositary share (ADS) represents one equity share. J.P. Morgan Chase Bank, N.A. is the depositary, and the ADSs trade on the New York Stock Exchange. So earnings per ADS equal earnings per share. Net income is the share belonging to the company's owners.

Learn: Fiscal years that don't end in December: Nvidia's FY2027 explained · Stock-based compensation and dilution: pay that becomes shares

07Who runs it

Who runs Dr. Reddy's, and did they deliver?

  • K. Satish Reddy

    Chairman

    A trustee of the VSD Family Trust, which held 9.06% of shares at Mar 31, 2026.

  • G.V. Prasad

    Co-Chairman and Managing Director

    A trustee of the GVP Family Trust, which held 11.51% of shares at Mar 31, 2026.

  • Erez Israeli

    Chief Executive Officer

    Holds options on ADSsA certificate a US bank (the depositary) issues for shares of a foreign company that it holds. It trades in US dollars on a US exchange, and one may stand for more than one share. Learn more, according to Item 6.E of the FY2026 20-F.

  • M.V. Narasimham

    Chief Financial Officer

    Named as Chief Financial Officer in the FY2026 20-F.

What they said, and what happened

1 too early to tell

  1. Said on May 12, 2026

    G.V. Prasad said in the Q4 FY2026 release: "We remain focused on strengthening our base business and improving margins, through cost efficiencies and portfolio optimization."

    What happened

    The statement names no target or date. Operating margin was 4.7% in Q1 FY2027 and 14.6% in Q2 FY2027, against 1.8% in Q4 FY2026 and 19.9% in Q2 FY2026 (Cityfort calculation from the Form 6-K results).

    Too early to tell

08What could go wrong

What could go wrong for Dr. Reddy's?

  • Concentration

    A few products can move results

    The 20-F says a limited number of products may account for a significant portion of revenue. North America revenue fell 22% in FY2026, which the company linked mainly to lower lenalidomide sales and a one-time claim.

    Watch North America revenue each quarter: INR 24,890 million in Q2 FY2027, against INR 32,408 million a year earlier.

  • Pricing

    Falling prices for US generics

    The 20-F says new manufacturers keep entering the US generic market, which may further lower its pricing power. Price changes cut Global Generics revenue by about 10% in FY2026, including the lenalidomide claim.

    Watch Price, volume and new-product effects in the next 20-F's segment review.

  • Regulation

    Manufacturing and quality

    Semaglutide batches found out of specification led to an INR 2,397 million provision in Q1 FY2027. A separate Canada recall reduced Q2 FY2027 revenue by INR 710 million, booked as expected returns.

    Watch Results of the US FDA inspections at the two Indian sites, reported in the 6-K releases.

  • Other

    Business in Russia

    Russia brought in INR 34,786 million, 10.4% of FY2026 revenue. Dr. Reddy's booked INR 1,836 million in FY2026 after a Federal Tax Service VAT audit of one of its foreign subsidiaries. It believes "the likelihood of any further liability that may arise on account of this field tax audit is not probable".

    Watch Russia's revenue and the company's notes on geopolitical conflicts in each 6-K.

  • Currency

    Rupee and other currencies

    Much of Dr. Reddy's revenue is in US dollars, euros, rubles, pounds and Brazilian reals, while much of its costs are in rupees, the 20-F says. FY2026 revenue rose 3% as reported but fell 2% excluding currency moves.

    Watch Reported growth against growth excluding currency moves in each 20-F.

  • Regulation

    US drug pricing rules and tariffs

    The 20-F says US drug pricing changes, including most-favored-nation requirements, and tariffs could hurt its prices and costs. North America brought in 33.9% of FY2026 revenue.

    Watch US pricing and tariff rules and the company's comments on them in its 6-K releases.

  • Legal

    US price-fixing lawsuits

    Lawsuits combined in a Philadelphia federal court since 2016 allege that certain US generic makers conspired on prices from about 2009. Dr. Reddy's US subsidiary is a defendant; the company believes the claims are "without merit", denies any wrongdoing and has made no provision.

    Watch Test trials expected in late 2026 or 2027, the 20-F says; in two of them the subsidiary is named for three drugs in total.

  • Governance

    Two families' influence

    The founding families and their trusts held 26.63% of shares at Mar 31, 2026. The 20-F says their influence could delay or prevent a change in control.

    Watch The families' holding in the next 20-F and any Schedule 13D amendment.

09Supporters vs. critics

What do supporters and critics point to?

Facts each side points to. We don't say which side is right.

What supporters point to

  • Dr. Reddy's was profitable in every year from FY2022 to FY2026, with profit for equity holders of INR 42,850 million in FY2026.
  • Revenue rose every year from FY2022 to FY2026, from INR 214,391 million to INR 335,933 million.
  • India revenue grew 17% and emerging markets revenue 24% year on year in Q2 FY2027.
  • At Sep 30, 2026, cash and current investments of INR 76,242 million were more than borrowings, not counting leases, of INR 58,260 million.
  • 80 US applications were waiting for approval at Sep 30, 2026, by the company's count.

What critics point to

  • North America revenue fell 22% in FY2026 and 23% year on year in Q2 FY2027.
  • Profit for equity holders was INR 9,250 million in Q2 FY2027, against INR 14,372 million a year earlier.
  • Operating profit per INR 100 of revenue was INR 15.0 in FY2026, down from INR 24.3 in FY2024.
  • Borrowings including leases rose from INR 46,766 million to INR 77,341 million during FY2026.
  • Out-of-specification semaglutide batches led to an INR 2,397 million provision in Q1 FY2027.

10What to watch next

What should you watch next at Dr. Reddy's?

Next event

Q3 FY2027 results (quarter ending Dec 31, 2026)

Date not announced yet.

  • North America after lenalidomide

    North America revenue was INR 24,890 million in Q2 FY2027, up from INR 22,048 million in Q1 FY2027 and down from INR 32,408 million a year earlier.

  • Semaglutide

    Generic semaglutide was approved in 10 countries by Oct 23, 2026. The Q1 FY2027 provision was INR 2,397 million and the Q2 FY2027 Canada recall INR 710 million.

  • Margins

    Operating profit per INR 100 of revenue was INR 14.6 in Q2 FY2027, against INR 19.9 a year earlier and INR 1.8 in Q4 FY2026.

11Key dates

What are the key dates for Dr. Reddy's?

Dates as stated in the filings. A date that no filing has given yet shows as not yet stated.
Key dates for Dr. Reddy's
EventDateSource
Fiscal 2027 endsDr. Reddy's fiscal year runs from Apr 1 to Mar 31.Form 20-F for FY2026 (year ended March 31, 2026)

Learn: Fiscal years that don't end in December: Nvidia's FY2027 explained

12Key facts

Key facts about Dr. Reddy's

What does Dr. Reddy's do?
Dr. Reddy's Laboratories is an Indian drug maker based in Hyderabad. It makes and sells generic and branded medicines and the active ingredients used in medicines, and had 27,527 employees at Mar 31, 2026.
How does Dr. Reddy's make money?
Dr. Reddy's earns most of its money selling finished medicines: its Global Generics segment brought in INR 299,033 million of FY2026 revenue of INR 335,933 million. Drug ingredients and contract services (its PSAI segment) brought in INR 34,773 million.
Who are Dr. Reddy's customers?
In North America, Dr. Reddy's sells mostly to retail chains, wholesalers and private-label customers, its FY2026 20-F says; in India it sells to about 6,500 wholesalers. North America paid 33.9% of FY2026 revenue and India 18.5% (Cityfort calculation from the FY2026 20-F).
How big is Dr. Reddy's?
Dr. Reddy's had revenue of INR 335,933 million and profit for equity holders of INR 42,850 million in FY2026 (year ended Mar 31, 2026), with 27,527 employees at Mar 31, 2026.
Is Dr. Reddy's profitable?
Yes. Dr. Reddy's profit for equity holders was INR 42,850 million in FY2026, INR 12.8 for every INR 100 of revenue, and it was profitable in every year from FY2022 to FY2026.
What is a Dr. Reddy's ADS?
A Dr. Reddy's American depositary share (ADS) trades on the New York Stock Exchange under the ticker RDY. Each ADS represents one Dr. Reddy's equity share, held by the depositary, J.P. Morgan Chase Bank, N.A., according to the FY2026 20-F.
Who owns Dr. Reddy's?
The families of Chairman K. Satish Reddy and Co-Chairman G.V. Prasad, with their family trusts, held 26.63% of Dr. Reddy's shares at Mar 31, 2026, according to the FY2026 20-F. Life Insurance Corporation of India and its associates held 12.16%.
Does Dr. Reddy's have debt?
Dr. Reddy's had borrowings of INR 58,260 million, not counting lease liabilities of INR 14,027 million, at Sep 30, 2026, against cash and current investments of INR 76,242 million (Cityfort calculation from Dr. Reddy's Q2 FY2027 Form 6-K).
What were Dr. Reddy's latest quarterly results?
In Q2 FY2027 (quarter ended Sep 30, 2026), Dr. Reddy's revenue was INR 86,708 million, down 1.5% from INR 88,051 million a year earlier. Profit for equity holders was INR 9,250 million, down from INR 14,372 million, and diluted EPS INR 11.10 against INR 17.25.
Does Dr. Reddy's pay dividends?
Yes. Dr. Reddy's paid INR 8 per equity share in each of FY2024, FY2025 and FY2026, counted after its 2024 share split. Its INR 8 dividend for FY2026 was approved on Jul 23, 2026, and the depositary converts dividends into US dollars for ADS holders.

Go deeper

More detail from the same filings. Open any section.

13What it sells

13What it sells

What does Dr. Reddy's sell?

Dr. Reddy's makes copies of medicines whose patents have expired, called generics, and sells them in North America, Europe and emerging markets. It also sells branded medicines in India and Russia, and drug ingredients to other drug makers.
  • Global Generics: finished medicines

    Medicines sold as generics or under brand names, including biosimilars and quit-smoking brands. The segment brought in INR 299,033 million, 89.0% of FY2026 revenue.

  • Generics in North America

    Generic tablets, injectables and store-brand over-the-counter products: INR 113,737 million in FY2026, down 22%. The company said in its Q4 FY2026 release that the fall was mainly due to lower lenalidomide sales and a one-time claim.

  • Nicotine replacement brands

    Nicotinell, Nicabate and related quit-smoking products outside the US, bought from Haleon in September 2024. They brought in INR 28,189 million in FY2026.

  • Branded medicines in India and emerging markets

    India revenue was INR 62,186 million in FY2026, up 16%, and Russia INR 34,786 million. IQVIA ranked Dr. Reddy's 10th by sales in India, with a 3.2% share, the 20-F says.

  • Drug ingredients and contract services (PSAI)

    Active pharmaceutical ingredients (API), the main ingredient in a medicine, sold to other drug makers, plus contract research and manufacturing. External revenue was INR 34,773 million in FY2026.

Think of it like this

Like a store-brand maker for medicines: once a patent expires, it makes a cheaper copy and competes on price with other copy makers.

What it does

  • Does: Makes generic and branded medicines and their active ingredients
  • Does: Sold 81% of FY2026 revenue outside India
  • Does: Launched 25 US products and made 15 US generic filings in FY2026

What it does not do

  • Does not: Report in US dollars: its 20-F figures are in Indian rupees
  • Does not: Sell its nicotine replacement brands in the US: the business bought from Haleon covers markets outside the US
  • Does not: Own its nutrition subsidiary alone: Nestlé India holds 49% of it
14How the money flows

14How the money flows · FY2026

How does money flow through Dr. Reddy's?

Money in

  • Revenue from customersINR 335,933M
  • Other income, finance income, share of associates' profit and the minority partner's share of lossesINR 12,277M

The company

Dr. Reddy's

INR 348,210M came in

Money out

  • Cost of revenues (making the products)INR 158,669M
  • Selling, general and administrativeINR 106,763M
  • Research and developmentINR 24,058M
  • Impairment (write-downs of assets)INR 3,519M
  • Income taxINR 12,351M
  • Profit attributable to Dr. Reddy's equity holdersINR 42,850M
  1. Customers paid Dr. Reddy's INR 335,933 million in FY2026 for medicines, drug ingredients and services.
  2. Making the products cost INR 158,669 million, leaving gross profit of INR 177,264 million.
  3. Selling, general and administrative costs took INR 106,763 million, research INR 24,058 million and write-downs INR 3,519 million.
  4. Other income of INR 7,627 million included INR 1,890 million from selling trademarks and INR 1,400 million from lawsuit settlements. Operating profit was INR 50,551 million.
  5. Finance income and associates added INR 4,266 million and income tax took INR 12,351 million. With the minority partner's INR 384 million share of losses, INR 42,850 million was left for equity holders.
15What it needs to run

15What it needs to run

What does Dr. Reddy's need to run?

  • People

    27,527 employees at Mar 31, 2026, of whom 24,650 worked in India.

  • Factories and research sites

    The 20-F puts FY2026 capital spending at INR 36,715 million, mainly for manufacturing and research facilities. A further INR 9,716 million was committed at Mar 31, 2026.

  • Research and approvals

    Research and development cost INR 24,058 million in FY2026, 7.2% of revenue. At Sep 30, 2026, 80 US applications awaited approval: 77 for generics (ANDAs) and 3 new drug applications (NDAs).

  • Bought product rights and brands

    Dr. Reddy's spent INR 15,099 million on intangible assets in FY2026. Purchases included the Stugeron brand and local brands for INR 4,464 million and Progynova trademarks in India for INR 3,014 million.

16Competitors and what protects it

16Competitors and what protects it

Who does Dr. Reddy's compete with?

Dr. Reddy's FY2026 20-F names Teva, Viatris, Sandoz, Sun Pharmaceuticals and Hikma as its major US competitors. In India, IQVIA ranked it 10th by sales, with a 3.2% share, in the year to Mar 31, 2026.
  • Teva

    NYSE: DECK

    Named in the FY2026 20-F as a major US generics competitor; also named in Russia.

  • Viatris Inc.

    Named in the FY2026 20-F as a major US generics competitor.

  • Sandoz

    Named in the FY2026 20-F as a major US generics competitor.

  • Sun Pharmaceuticals Limited

    An Indian drug maker named in the FY2026 20-F as a major US generics competitor.

  • Hikma Pharmaceuticals plc

    Named in the FY2026 20-F as a major US generics competitor.

What protects the business

Each strength is scored 1 (weak) to 5 (strong) for the business, with the reason. It is not a rating of the share.

  • Spread across markets3 of 5

    No market brought in more than 34% of FY2026 revenue: North America 33.9%, India 18.5%, Europe 16.5% and Russia 10.4%.

  • US filings waiting for approval3 of 5

    80 US applications were pending at Sep 30, 2026; 46 challenge a brand's patent and 27 may be the first such filing, the company says.

  • Brands in India3 of 5

    IQVIA ranked Dr. Reddy's 10th in India by sales, with a 3.2% share, in the year to Mar 31, 2026, the 20-F says.

Weak spot

A few US products

The 20-F says "a limited number of products may account for a significant portion of our revenues". North America revenue fell 22% in FY2026.

17Where growth could come from

17Where growth could come from

Where could Dr. Reddy's' growth come from?

On Oct 23, 2026, Co-Chairman and Managing Director G.V. Prasad said the company remains focused on "strengthening our core businesses, enhancing productivity, and investing in strategic growth platforms". The releases used for this page give no revenue or profit forecast.
Management statement, Oct 23, 2026. Reported as a statement, not our forecast.
  • Branded medicines in India and emerging markets

    Working

    +17% and +24% year on year, Q2 FY2027

    India revenue was INR 18,508 million in Q2 FY2027. Emerging markets revenue rose to INR 20,595 million from INR 16,548 million, with Russia up 15%.

    Status: Working, on track against what the company said.

  • Nicotine replacement brands

    Mixed

    INR 28,189 million in FY2026

    The brands bought from Haleon brought in INR 12,020 million in the part of FY2025 after the deal. In Q2 FY2027 their revenue fell 6% from a year earlier, the company said.

    Status: Mixed, partly on track.

  • Generic semaglutide

    Early

    Approved in 10 countries by Oct 23, 2026

    Dr. Reddy's launched it in Canada in May 2026, after receiving the first marketing authorization there for a generic semaglutide injection. Some batches were found out of specification in Q1 FY2027, and a separate Canada recall began in August 2026.

    Status: Early, too early to judge.

  • Generics in North America

    Behind

    -23% year on year, Q2 FY2027

    North America revenue was INR 24,890 million, against INR 32,408 million a year earlier. The company said the decline was largely due to lower lenalidomide sales.

    Status: Behind, behind the company's own plan.

  • Biosimilars through partners

    Early

    No separate biosimilar revenue figure is shown on this page

    Biosimilars are close copies of biological drugs. The 20-F names partnerships with Alvotech (2024, a denosumab biosimilar) and Shanghai Henlius Biotech (2025, a daratumumab biosimilar) for the US and Europe.

    Status: Early, too early to judge.

Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.

18The company's own measures (non-GAAP)

18The company's own measures · FY2026 (year ended Mar 31, 2026), unless stated

What do Dr. Reddy's' own measures show?

Dr. Reddy's EBITDA, free cash flow and net cash surplus are its own measures, shown next to the official IFRS number. They are never added together.
  • Official (IFRS): Results from operating activities (IFRS), FY2026

    INR 50,551M

    Company's own measure: EBITDA (Dr. Reddy's measure), FY2026

    INR 76,595M

    Dr. Reddy's starts from profit before tax, removes finance and investment income, and adds back depreciation, amortization and INR 3,520 million of impairment. "The numbers" shows INR 71,156 million: operating profit plus depreciation and amortization.

  • Official (IFRS): Operating margin (IFRS), Q2 FY2027

    14.6%

    Company's own measure: EBITDA margin (Dr. Reddy's measure), Q2 FY2027

    20.6%

    The company's EBITDAOperating profit before wear-and-tear charges (depreciation and amortization). As a margin: per $100 of sales. of INR 17,828 million ÷ revenue of INR 86,708 million. The IFRS margin is a Cityfort calculation from the Q2 FY2027 Form 6-K: operating profit of INR 12,683 million ÷ revenue.

  • Official (IFRS): Net cash from operating activities (IFRS), FY2026

    INR 56,755M

    Company's own measure: Free cash flow (Dr. Reddy's definition), FY2026

    INR 20,040M

    The company takes cash generated from operations after taxes and subtracts INR 36,715 million of spending on property, plant, equipment and intangible assets; after INR 3,152 million of acquisition payments it was INR 16,888 million. "The numbers" shows INR 33,429 million, which subtracts only property, plant and equipment.

  • Official (IFRS): Cash and cash equivalents (IFRS), Sep 30, 2026

    INR 13,294M

    Company's own measure: Net cash surplus (Dr. Reddy's measure), Sep 30, 2026

    INR 25,024M

    Cash and investments less borrowings, leaving out lease liabilities of INR 14,027 million, restricted cash and equity investments. It was INR 32,714 million at Mar 31, 2026.

These are the company's own measures, defined by the company. They are not comparable across companies, and they are not added together. Each sits beside the nearest official (IFRS) figure.

Learn: Non-GAAP measures: what a company's "adjusted" numbers leave out

19Financial strength and debt

19Financial strength · Sep 30, 2026

How much debt does Dr. Reddy's have?

At Sep 30, 2026, Dr. Reddy's had INR 76,242 million of cash and current investments against borrowings of INR 58,260 million, not counting leases: net cash of INR 17,982 million (Cityfort calculation from the Q2 FY2027 Form 6-K).
  • Total debtINR 58,260M
  • Cash and investmentsINR 76,242M
  • Net cash (cash minus debt)INR 17,982M
  • Net worth (shareholders' money)INR 386,179M
Debt to equity
0.15×
INR of debt for every INR 1 of shareholders' money
  • Cash and current investments is a Cityfort calculation from the Q2 FY2027 Form 6-K: cash of INR 13,294 million plus current investments of INR 62,948 million. Non-current investments of INR 10,428 million are left out.
  • Lease liabilities of INR 14,027 million are not counted as debt here; with them, borrowings were INR 72,287 million at Sep 30, 2026.
  • Dr. Reddy's own measure, "net cash surplus", was INR 25,024 million at Sep 30, 2026. It leaves out lease liabilities, restricted cash and equity investments, and counts non-current investments.
  • Borrowings including leases rose from INR 46,766 million at Mar 31, 2025 to INR 77,341 million at Mar 31, 2026. Short-term borrowings rose from INR 38,045 million to INR 59,135 million.
  • Equity attributable to equity holders was INR 386,179 million at Sep 30, 2026. Other intangible assets, mostly product rights and brands, were INR 105,059 million at Mar 31, 2026.
20Who owns it

20Who owns it · ownership as of Mar 31, 2026

Who owns Dr. Reddy's?

Each equity share carries one vote, and there is one class of shares. The FY2026 20-F says the full-time executive directors and their immediate families beneficially owned 26.63% of issued shares at Mar 31, 2026. BlackRock reported 5.3% at Sep 30, 2024 and 4.1% at Mar 31, 2025 in its Schedule 13G filings.
Share classes
Dr. Reddy's share classes: shares outstanding (millions) and votes per share
ClassShares (millions)Votes per shareHeld by% of shares% of votesTraded
Equity shares (834,656,970 shares at Mar 31, 2026. At Sep 30, 2026, 834,680,285 shares were issued, including 1,607,435 treasury shares held by an employee stock option trust: 833,072,850 net. The shares trade in India; ADSs trade on the New York Stock Exchange, one ADS per share.)834.71The two founding families and their trusts, Life Insurance Corporation of India, the depositary for ADS holders, other institutions and the public100.0%100.0%Yes
Holders of 5% or more
Dr. Reddy's holders of 5% or more, from the Form 20-F or later Schedule 13G filings; each row shows its own date
HolderSharesVotesAs ofSourceNote
The K. Satish Reddy and G.V. Prasad families and their trusts26.6%–Mar 31, 2026S1, S14222,305,640 shares, including the GVP Family Trust (11.51%), with G.V. Prasad among its trustees, and the VSD Family Trust (9.06%), with K. Satish Reddy among its trustees. A Schedule 13D/A filed on Sep 18, 2025 reported transfers into the trusts on Sep 17, 2025.
Life Insurance Corporation of India and associates12.2%–Mar 31, 2026S1101,502,343 shares, up from 7.19% at Mar 31, 2025 and 5.05% at Mar 31, 2024.
J.P. Morgan Chase Bank, N.A. (depositary)11.9%–Mar 31, 2026S1Holds the equity shares behind the ADSs, according to the FY2026 20-F.

One American depositary share (ADS) represents one equity share. J.P. Morgan Chase Bank, N.A. is the depositary, and the ADSs trade on the New York Stock Exchange. Each ADS holder owns the shares through the depositary, so the ADSs are not a separate share class.

From the company's annual report on Form 20-F (Items 6.E and 7.A), later Schedule 13G filings and the share count in that report. Each holder row shows the date of its own filing.

21What it does with profit

21What it does with profit

What does Dr. Reddy's do with its profit?

Dividends are the amounts paid per equity share in each fiscal year, counted after the five-for-one split of October 2024 (INR 40 before it). Each year's payment was the final dividend for the year before: FY2026's INR 6,659 million paid the FY2025 dividend. The INR 8 dividend for FY2026 was approved on Jul 23, 2026, and INR 6,664 million was paid in the half to Sep 30, 2026. The depositary converts dividends into US dollars for ADS holders.

Dividend per share

INR 8.00FY2026

Dividend paid for each share, by financial year.

INR per share

See the numbers
Dividend per share (INR per share)
YearDividend per shareShare of profit paid out
FY2024INR 8.00–
FY2025INR 8.00–
FY2026INR 8.00–

No buybacks or fund raises in the period covered.

22Governance signals

22Governance signals

What do Dr. Reddy's' governance filings show?

Auditor
Deloitte Haskins & Sells, LLP, since 2026
Auditor changes
Jul 22, 2026: Ernst & Young Associates LLP → Deloitte Haskins & Sells, LLP (Approved on the Audit Committee's recommendation; Deloitte will audit the FY2027 20-F and review interim statements. The Q2 FY2027 report gives no reason for the change.)
Audit qualifications
None reported
Related-party dealings
This page does not summarize related-party transactions; the notes to the FY2026 20-F's financial statements list them.
Credit rating
Not checked for this page

Flags to know about

  • other

    Two founding families hold about a quarter of the shares

    The families of K. Satish Reddy and G.V. Prasad and their trusts held 26.63% of shares at Mar 31, 2026. The 20-F says they are likely to have "significant influence over most matters requiring approval by our shareholders".

  • regulatory

    US anti-corruption inquiry closed

    The SEC and the DOJ looked into an anonymous complaint, received in September 2020, alleging improper payments to healthcare professionals in Ukraine and potentially other countries. In a letter received on Feb 23, 2026, the SEC said that, based on the information available to it, it "does not intend to recommend any enforcement action against the Company at this time". On Mar 5, 2026, the DOJ said it "has closed its inquiry".

  • regulatory

    US FDA inspection findings

    The US FDA issued Form 483 inspection findings at two sites in India in July and August 2026, with three and four observations. The company said its responses were "provided within the stipulated timeline".

23What the market paid

23What the market paid · price as of Nov 16, 2026

What did the market pay for Dr. Reddy's on Nov 16, 2026?

Price as of Nov 16, 2026 (shown for education; prices change daily).

ADS price (NYSE) as of Nov 16, 2026: $14.70, the closing price in Nasdaq.com's historical price table for RDY; the ADSs are listed on the New York Stock Exchange. One ADS represents one equity share, so with 833,072,850 shares outstanding at Sep 30, 2026 (net of treasury shares), the market value is about $12,246 million (Cityfort calculation from the Nov 16, 2026 closing price and the Q2 FY2027 report on Form 6-K). No P/E, P/B or EV/EBITDA is shown: Dr. Reddy's reports earnings and equity in Indian rupees, so dividing them into a US-dollar price would mix two currencies.

ADS price (NYSE)
$14.70
Market value (market cap)
$12.2B

Source: RDY historical daily prices, Nov 2 to Nov 16, 2026 (Nasdaq.com table for the NYSE-listed ADS; close of Nov 16, 2026: $14.70); Form 6-K: Q2 FY2027 report (interim condensed consolidated financial statements)

24How it got here

24How it got here

How did Dr. Reddy's get here?

  1. 1984

    Milestone

    Founded in Hyderabad

    Incorporated on Feb 24, 1984 by the late Dr. K. Anji Reddy, the company's former Chairman, to develop and supply pharmaceutical products.

  2. 2001

    Milestone

    ADSs listed in New York

    Its ADSs have been listed on the New York Stock Exchange since Apr 11, 2001.

  3. 2024

    Business-model change

    Quit-smoking brands bought; shares split

    Completed the purchase of Haleon's nicotine replacement business outside the US in September 2024, paying INR 51,407 million at closing. A five-for-one share split followed, with a record date of Oct 28, 2024; each ADS still represents one share.

  4. 2025

    Milestone

    Family shares moved into trusts

    On Sep 17, 2025, family members moved shares into the GVP and VSD Family Trusts, according to a Schedule 13D/A filed the next day.

  5. 2026

    Crisis

    Lenalidomide claim and write-downs

    In Q4 FY2026 (Jan to Mar 2026), Dr. Reddy's booked an INR 4,530 million lenalidomide claim against revenue, discontinued certain CAR-T research programs and wrote down eftilagimod alfa. Profit for equity holders that quarter was INR 2,201 million.

  6. 2026

    Milestone

    Semaglutide launched in Canada, then a recall

    Launched generic semaglutide in Canada in May 2026. In August 2026 it began recalling some batches there for an impurity and a labeling error.

25Sources and changes

Where every number on this page comes from

Sources (17 documents)
  1. S1Form 20-F for FY2026 (year ended March 31, 2026) · Dr. Reddy's Laboratories Limited (SEC EDGAR) · Tier 1: company or exchange filing · May 29, 2026
  2. S2Form 20-F for FY2025 (year ended March 31, 2025) · Dr. Reddy's Laboratories Limited (SEC EDGAR) · Tier 1: company or exchange filing · Jun 6, 2025
  3. S4Form 20-F for FY2023 (year ended March 31, 2023) · Dr. Reddy's Laboratories Limited (SEC EDGAR) · Tier 1: company or exchange filing · Jun 13, 2023
  4. S5Form 20-F for FY2022 (year ended March 31, 2022) · Dr. Reddy's Laboratories Limited (SEC EDGAR) · Tier 1: company or exchange filing · Jun 27, 2022
  5. S6Form 6-K: Q2 FY2027 results under IFRS (Exhibit 99.3) · Dr. Reddy's Laboratories Limited (SEC EDGAR) · Tier 1: company or exchange filing · Oct 23, 2026
  6. S7Form 6-K: Q2 FY2027 earnings release (Exhibit 99.2) · Dr. Reddy's Laboratories Limited (SEC EDGAR) · Tier 1: company or exchange filing · Oct 23, 2026
  7. S8Form 6-K: Q2 FY2027 report (interim condensed consolidated financial statements) · Dr. Reddy's Laboratories Limited (SEC EDGAR) · Tier 1: company or exchange filing · Oct 23, 2026
  8. S9Form 6-K: Q4 FY2026 results under IFRS (Exhibit 99.3) · Dr. Reddy's Laboratories Limited (SEC EDGAR) · Tier 1: company or exchange filing · May 12, 2026
  9. S10Form 6-K: Q4 FY2026 earnings release (Exhibit 99.2) · Dr. Reddy's Laboratories Limited (SEC EDGAR) · Tier 1: company or exchange filing · May 12, 2026
  10. S11Form 6-K: Q3 FY2026 results under IFRS (Exhibit 99.2) · Dr. Reddy's Laboratories Limited (SEC EDGAR) · Tier 1: company or exchange filing · Jan 21, 2026
  11. S12Form 6-K: Q1 FY2026 results under IFRS (Exhibit 99.3) · Dr. Reddy's Laboratories Limited (SEC EDGAR) · Tier 1: company or exchange filing · Jul 23, 2025
  12. S13Form 6-K: Q1 FY2026 earnings release (Exhibit 99.2) · Dr. Reddy's Laboratories Limited (SEC EDGAR) · Tier 1: company or exchange filing · Jul 23, 2025
  13. S14Schedule 13D/A (Amendment No. 6) by G.V. Prasad, K. Satish Reddy and family trusts · SEC EDGAR · Tier 1: company or exchange filing · Sep 18, 2025
  14. S15Schedule 13G/A (Amendment No. 1) by BlackRock, Inc. · SEC EDGAR · Tier 1: company or exchange filing · Apr 28, 2025
  15. S16Schedule 13G by BlackRock, Inc. · SEC EDGAR · Tier 1: company or exchange filing · Oct 24, 2024
  16. S17Form F-6 registration of American Depositary Shares (stock split) · SEC EDGAR · Tier 1: company or exchange filing · Oct 23, 2024
  17. S18RDY historical daily prices, Nov 2 to Nov 16, 2026 (Nasdaq.com table for the NYSE-listed ADS; close of Nov 16, 2026: $14.70) · Nasdaq, Inc. · Tier 1: company or exchange filing · Nov 17, 2026
Changes to this page (v1 · Nov 17, 2026)
  1. v1 · Nov 17, 2026First version. (first version)

Numbers come only from tier 1 and tier 2 sources. Read how we research.

Disclaimer

For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a registered investment adviser or other qualified professional.

Cityfort, its owners and contributors may or may not hold securities of companies covered. Cityfort is not paid by any company it covers. Content is not an offer or solicitation to buy or sell any security, including in any initial public offering.

Read the positions policy
Read the full disclaimer

Cityfort publishes general educational content that explains how listed companies work. Cityfort is not registered with the US Securities and Exchange Commission or any state securities regulator as an investment adviser, and is not a broker-dealer or a member of FINRA. Cityfort does not provide investment, tax or legal advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security. Nothing on the site is tailored to any person's circumstances.

All information is taken from publicly available sources, mainly company filings with the SEC, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.

Statements by company management, including forward-looking statements and guidance, are reported as the company's statements, with their date and source; they are not our forecasts. Adjusted (non-GAAP) figures are the company's own measures and are shown next to the official (GAAP) figures.